RDTCF (Rapid Dose Therapeutics) Beneish M-Score: 0.00 (As of Jul. 08, 2026)


RDTCF Rapid Dose Therapeutics Corp RDTCF
27 GF Score
Price $0.08
GF Value $0.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics Beneish M-Score?

Rapid Dose Therapeutics RDTCF -11.11% 27 Beneish M-Score is 0.00 as of Jul. 08, 2026. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 822 Biotechnology companies, Rapid Dose Therapeutics ranks worse than 121654.38% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Rapid Dose Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Rapid Dose Therapeutics was 615.54. The lowest was -11.93. And the median was -9.44.

Rapid Dose Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics Beneish M-Score Chart

Rapid Dose Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rapid Dose Therapeutics Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -5.12 0.00

RDTCF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Rapid Dose Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Beneish M-Score falls into.


RDTCF
27GF Score
Rapid Dose Therapeutics Corp RDTCF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Rapid Dose Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Nov25) TTM:Last Year (Nov24) TTM:
Total Receivables was $0.18 Mil.
Revenue was 0.467 + 0.488 + 0.565 + 0.468 = $1.99 Mil.
Gross Profit was 0.221 + 0.273 + 0.283 + 0.227 = $1.00 Mil.
Total Current Assets was $0.47 Mil.
Total Assets was $2.70 Mil.
Property, Plant and Equipment(Net PPE) was $2.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.33 Mil.
Selling, General, & Admin. Expense(SGA) was $2.81 Mil.
Total Current Liabilities was $5.86 Mil.
Long-Term Debt & Capital Lease Obligation was $1.56 Mil.
Net Income was -0.812 + -0.598 + -0.522 + -1.176 = $-3.11 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -0.19 + -0.19 + -0.314 + 0.003 = $-0.69 Mil.
 Total Receivables was $0.18 Mil.
Revenue was 0.359 + 0.378 + 0.292 + 0.143 = $1.17 Mil.
Gross Profit was 0.193 + 0.24 + 0.188 + 0.078 = $0.70 Mil.
Total Current Assets was $0.46 Mil.
Total Assets was $1.20 Mil.
Property, Plant and Equipment(Net PPE) was $0.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.27 Mil.
Selling, General, & Admin. Expense(SGA) was $3.03 Mil.
Total Current Liabilities was $2.26 Mil.
Long-Term Debt & Capital Lease Obligation was $1.87 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.184 / 1.988) / (0.178 / 1.172)
=0.092555 / 0.151877
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.699 / 1.172) / (1.004 / 1.988)
=0.596416 / 0.50503
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.472 + 2.225) / 2.696) / (1 - (0.457 + 0.738) / 1.195)
=-0.000371 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.988 / 1.172
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.266 / (0.266 + 0.738)) / (0.327 / (0.327 + 2.225))
=0.26494 / 0.128135
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.814 / 1.988) / (3.031 / 1.172)
=1.415493 / 2.586177
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.564 + 5.859) / 2.696) / ((1.868 + 2.264) / 1.195)
=2.753338 / 3.457741
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.108 - 0 - -0.691) / 2.696
=-0.896513

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Rapid Dose Therapeutics (RDTCF) has a Beneish M-Score of 0.00 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Rapid Dose Therapeutics and its competitors. According to the industry distribution chart, Rapid Dose Therapeutics ranks #999999 out of 822 companies in the Biotechnology industry.
Is Rapid Dose Therapeutics' Beneish M-Score too high?
Rapid Dose Therapeutics' current Beneish M-Score is 0.00. Based on the distribution chart, Rapid Dose Therapeutics ranks #999999 out of 822 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #999999 out of 822 companies for Beneish M-Score. This places Rapid Dose Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Beneish M-Score is 0.00. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Beneish M-Score is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • Beneish M-Score: 0.00
  • GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score

Get the complete analysis for RDTCF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.30
GF Value